Cargando…

NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging

INTRODUCTION: Current monoanalyte biomarkers are ineffective in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). NETest, a novel multianalyte signature, provides molecular information relevant to disease biology. AIM(S): Independently validate NETest to diagnose GEP-NETs and identify progres...

Descripción completa

Detalles Bibliográficos
Autores principales: Malczewska, Anna, Witkowska, Magdalena, Makulik, Karolina, Bocian, Agnes, Walter, Agata, Pilch-Kowalczyk, Joanna, Zajęcki, Wojciech, Bodei, Lisa, Oberg, Kjell, Kos-Kudła, Beata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479193/
https://www.ncbi.nlm.nih.gov/pubmed/30865931
http://dx.doi.org/10.1530/EC-19-0030
_version_ 1783413297764106240
author Malczewska, Anna
Witkowska, Magdalena
Makulik, Karolina
Bocian, Agnes
Walter, Agata
Pilch-Kowalczyk, Joanna
Zajęcki, Wojciech
Bodei, Lisa
Oberg, Kjell
Kos-Kudła, Beata
author_facet Malczewska, Anna
Witkowska, Magdalena
Makulik, Karolina
Bocian, Agnes
Walter, Agata
Pilch-Kowalczyk, Joanna
Zajęcki, Wojciech
Bodei, Lisa
Oberg, Kjell
Kos-Kudła, Beata
author_sort Malczewska, Anna
collection PubMed
description INTRODUCTION: Current monoanalyte biomarkers are ineffective in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). NETest, a novel multianalyte signature, provides molecular information relevant to disease biology. AIM(S): Independently validate NETest to diagnose GEP-NETs and identify progression in a tertiary referral center. MATERIALS AND METHODS: Cohorts are 67 pancreatic NETs (PNETs), 44 small intestine NETs (SINETs) and 63 controls. Well-differentiated (WD) PNETs, n = 62, SINETs, all (n = 44). Disease extent assessment at blood draw: anatomical (n = 110) CT (n = 106), MRI (n = 7) and/or functional (68)Ga-SSA-PET/CT (n = 69) or (18)F-FDG-PET/CT (n = 8). Image-positive disease (IPD) was defined as either CT/MRI or (68)Ga-SSA-PET/CT/(18)F-FDG-PET/CT-positive. Both CT/MRI and (68)Ga-SSA-PET/CT negative diagnosis in WD-NETs was considered image-negative disease (IND). NETest (normal: 20): PCR (spotted plates). Data: mean ± SD. RESULTS: DIAGNOSIS: NETest was significantly increased in NETs (n = 111; 26 ± 21) vs controls (8 ± 4, p < 0.0001). Seventy-five (42 PNET, 33 SINET) were image positive. Eleven (8 PNET, 3 SINET; all WD) were IND. In IPD, NETest was significantly higher (36 ± 22) vs IND (8 ± 7, P < 0.0001). NETest accuracy, sensitivity and specificity are 97, 99 and 95%, respectively CONCORDANCE WITH IMAGING: NETest was 92% (101/110) concordant with anatomical imaging, 94% (65/69) with (68)Ga-SSA-PET/CT and 96% (65/68) dual modality (CT/MRI and (68)Ga-SSA-PET/CT). In 70 CT/MRI positive, NETest was elevated in all (37 ± 22). In 40 CT/MRI negative, NETest was normal (11 ± 10) in 31. In 56 (68)Ga-SSA-PET/CT positive, NETest was elevated (36 ± 22) in 55. In 13 (68)Ga-SSA-PET/CT negative, NETest was normal (9 ± 8) in ten. DISEASE STATUS: NETest was significantly higher in progressive (61 ± 26; n = 11) vs stable disease (29 ± 14; n = 64; P < 0.0001) (RECIST 1.1). CONCLUSION: NETest is an effective diagnostic for PNETs and SINETs. Elevated NETest is as effective as imaging in diagnosis and accurately identifies progression.
format Online
Article
Text
id pubmed-6479193
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-64791932019-04-26 NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging Malczewska, Anna Witkowska, Magdalena Makulik, Karolina Bocian, Agnes Walter, Agata Pilch-Kowalczyk, Joanna Zajęcki, Wojciech Bodei, Lisa Oberg, Kjell Kos-Kudła, Beata Endocr Connect Research INTRODUCTION: Current monoanalyte biomarkers are ineffective in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). NETest, a novel multianalyte signature, provides molecular information relevant to disease biology. AIM(S): Independently validate NETest to diagnose GEP-NETs and identify progression in a tertiary referral center. MATERIALS AND METHODS: Cohorts are 67 pancreatic NETs (PNETs), 44 small intestine NETs (SINETs) and 63 controls. Well-differentiated (WD) PNETs, n = 62, SINETs, all (n = 44). Disease extent assessment at blood draw: anatomical (n = 110) CT (n = 106), MRI (n = 7) and/or functional (68)Ga-SSA-PET/CT (n = 69) or (18)F-FDG-PET/CT (n = 8). Image-positive disease (IPD) was defined as either CT/MRI or (68)Ga-SSA-PET/CT/(18)F-FDG-PET/CT-positive. Both CT/MRI and (68)Ga-SSA-PET/CT negative diagnosis in WD-NETs was considered image-negative disease (IND). NETest (normal: 20): PCR (spotted plates). Data: mean ± SD. RESULTS: DIAGNOSIS: NETest was significantly increased in NETs (n = 111; 26 ± 21) vs controls (8 ± 4, p < 0.0001). Seventy-five (42 PNET, 33 SINET) were image positive. Eleven (8 PNET, 3 SINET; all WD) were IND. In IPD, NETest was significantly higher (36 ± 22) vs IND (8 ± 7, P < 0.0001). NETest accuracy, sensitivity and specificity are 97, 99 and 95%, respectively CONCORDANCE WITH IMAGING: NETest was 92% (101/110) concordant with anatomical imaging, 94% (65/69) with (68)Ga-SSA-PET/CT and 96% (65/68) dual modality (CT/MRI and (68)Ga-SSA-PET/CT). In 70 CT/MRI positive, NETest was elevated in all (37 ± 22). In 40 CT/MRI negative, NETest was normal (11 ± 10) in 31. In 56 (68)Ga-SSA-PET/CT positive, NETest was elevated (36 ± 22) in 55. In 13 (68)Ga-SSA-PET/CT negative, NETest was normal (9 ± 8) in ten. DISEASE STATUS: NETest was significantly higher in progressive (61 ± 26; n = 11) vs stable disease (29 ± 14; n = 64; P < 0.0001) (RECIST 1.1). CONCLUSION: NETest is an effective diagnostic for PNETs and SINETs. Elevated NETest is as effective as imaging in diagnosis and accurately identifies progression. Bioscientifica Ltd 2019-03-13 /pmc/articles/PMC6479193/ /pubmed/30865931 http://dx.doi.org/10.1530/EC-19-0030 Text en © 2019 The authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Research
Malczewska, Anna
Witkowska, Magdalena
Makulik, Karolina
Bocian, Agnes
Walter, Agata
Pilch-Kowalczyk, Joanna
Zajęcki, Wojciech
Bodei, Lisa
Oberg, Kjell
Kos-Kudła, Beata
NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging
title NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging
title_full NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging
title_fullStr NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging
title_full_unstemmed NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging
title_short NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging
title_sort netest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479193/
https://www.ncbi.nlm.nih.gov/pubmed/30865931
http://dx.doi.org/10.1530/EC-19-0030
work_keys_str_mv AT malczewskaanna netestliquidbiopsyisdiagnosticofsmallintestineandpancreaticneuroendocrinetumorsandcorrelateswithimaging
AT witkowskamagdalena netestliquidbiopsyisdiagnosticofsmallintestineandpancreaticneuroendocrinetumorsandcorrelateswithimaging
AT makulikkarolina netestliquidbiopsyisdiagnosticofsmallintestineandpancreaticneuroendocrinetumorsandcorrelateswithimaging
AT bocianagnes netestliquidbiopsyisdiagnosticofsmallintestineandpancreaticneuroendocrinetumorsandcorrelateswithimaging
AT walteragata netestliquidbiopsyisdiagnosticofsmallintestineandpancreaticneuroendocrinetumorsandcorrelateswithimaging
AT pilchkowalczykjoanna netestliquidbiopsyisdiagnosticofsmallintestineandpancreaticneuroendocrinetumorsandcorrelateswithimaging
AT zajeckiwojciech netestliquidbiopsyisdiagnosticofsmallintestineandpancreaticneuroendocrinetumorsandcorrelateswithimaging
AT bodeilisa netestliquidbiopsyisdiagnosticofsmallintestineandpancreaticneuroendocrinetumorsandcorrelateswithimaging
AT obergkjell netestliquidbiopsyisdiagnosticofsmallintestineandpancreaticneuroendocrinetumorsandcorrelateswithimaging
AT koskudłabeata netestliquidbiopsyisdiagnosticofsmallintestineandpancreaticneuroendocrinetumorsandcorrelateswithimaging